FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
Genzyme is a global biopharmaceutical company helping patients in more than 100 countries. Genzyme is Sanofi’s global center of excellence in rare diseases and multiple sclerosis (MS). In Geel, Belgium, Genzyme has a manufacturing facility to produce therapeutic protein products through cell culture. The main product is recombinant alpha-glucosidase, the enzyme replacement therapy for Pompe disease, a rare genetic, often fatal, disease of the muscle.
Genzyme's commitment to innovation continues today with research into novel approaches to genetic disease, heart disease, and other areas of unmet medical need. Genzyme employees in offices around the globe serve patients in over 100 countries.
Genzyme BVBA founded in 2001 located in Geel, a large manufacturing site for biopharmaceuticals (employees >530).
Genzyme has strong development programs using multiple technologies to genetic diseases, cardiovascular diseases, and immune diseases. In research and development, the company takes a pragmatic approach that gives freedom to apply diverse technologies to specific medical areas. These technologies include proteins, polymers, small molecules, biomaterials, cell therapy and gene therapy.
Personalized Genetic Health and Cardiovascular:
Genzyme seeks strategic collaborations to expand its portfolio of commercialized products and services, to supplement its product pipeline, and to access complementary research, technology, and development capabilities. The company focuses on first-rate science and on opportunities that address well-defined patient populations with unmet or underserved medical need.
Some major partnerships: